Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
OncLive,
Danny Rischin, MD In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates…
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.
Overview of attention for article published in Journal of Clinical Oncology, May 2020
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (79th percentile)
-
Good Attention Score compared to outputs of the same age and source (67th percentile)
Readers on
- mendeley
- 6 Mendeley